ePocrates Survey Reveals Psychiatrists Expect to Increase Usage of Abilify.

Publication: PR Newswire

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2003 PR Newswire Association LLC

SAN MATEO, Calif. -- SAN MATEO, Calif., June 4 /PRNewswire/ -- According to a survey conducted by ePocrates, an overwhelming majority of psychiatrists say that their usage of the anti-psychotic Abilify will increase based on the findings of a head-to-head clinical trial that pitted relative newcomer Abilify against category powerhouse Zyprexa.

The results of the head-to-head trial were presented at the 153rd Annual Meeting of the American Psychiatric Association. The trial results showed that a significantly greater number of patients with schizophrenia who were treated with Eli Lilly's Zyprexa experienced clinically significant weight gain compared to those treated with...

Read the full article for free courtesy of your local library.